Pharmabiz
 

US FDA seeks more data from J&J's bipolar disorder drug risperidone

Titusville, New JerseyThursday, February 12, 2009, 08:00 Hrs  [IST]

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced that the Food and Drug Administration (FDA) has asked for additional information regarding the company's supplemental New Drug Application (sNDA) for Risperdal Consta (risperidone) long-acting injection. The sNDA, submitted in April 2008, sought approval for Risperdal Consta for adjunctive maintenance treatment to delay the occurrence of mood episodes in patients with bipolar disorder who relapsed frequently. The Agency's complete response outlined questions that need to be addressed prior to granting approval for the new indication, but did not request additional studies. J&JPRD is currently evaluating the FDA's complete response letter and will work with the Agency to resolve any outstanding questions. Bipolar disorder is a brain disorder that causes unusual shifts in a person's mood, energy and ability to function. It is often characterized by debilitating mood swings from extreme highs (mania) to extreme lows (depression), and affects 5.7 million, or 2.6 percent, of the American adult population in any given year. Risperdal Consta is marketed in the US by Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and manufactured by Alkermes, Inc. Risperdal Consta was initially approved for the treatment of schizophrenia in the US in 2003 and is registered in more than 80 countries worldwide. Using Alkermes' proprietary Medisorb drug-delivery technology, the Risperdal Consta formulation encapsulates risperidone in microspheres made of a biodegradable polymer, which are suspended in a water-based solution and injected into the muscle. Laboratory and clinical research has shown that the microspheres gradually degrade at a set rate to provide therapeutic blood levels of the drug in the bloodstream for an extended period. The polymer from which the microspheres are made breaks down into two naturally occurring compounds that are then eliminated by the body. Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., based in Titusville, New Jersey, is the only pharmaceutical company in the US dedicated solely to mental health. The company currently markets prescription medications for the treatment of schizophrenia, bipolar mania, and irritability associated with autistic disorder.

 
[Close]